Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-06-04 Director's Dealing
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership by an executive (Park Seung-kook) of HanAll Biopharma. This type of filing is specifically categorized as a Director's Dealing (insider transaction) report.
2024-06-04 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) from HanAll Biopharma. It details specific share transactions by company executives (directors) resulting from stock grants. This falls under the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives.
2024-06-04 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Results of Disposal of Treasury Shares' (자기주식처분결과보고서) filed by HanAll Biopharma. It details the specific number of shares disposed of, the price, and the purpose (stock grant/compensation). This falls under the category of a company reporting the disposal or transaction of its own shares.
2024-06-04 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from HanAll Biopharma regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing details the company's plan to dispose of its own shares for employee stock grants. According to the provided definitions, a report of a company buying back or selling its own shares is classified as 'Transaction in Own Shares' (POS).
2024-06-03 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from HanAll Biopharma regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing a conditional licensing agreement for mRNA technology with Turn Biotechnologies. This type of disclosure, which details a specific business transaction or material event, falls under the category of general regulatory announcements as it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of entities) or capital financing. Therefore, it is classified as a Regulatory Filing (RNS).
2024-05-27 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for HanAll Biopharma Co., Ltd. for the period of January 1, 2024, to March 31, 2024. It contains detailed financial statements, management discussion and analysis, and operational information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.